Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$109.84

1.9 (1.76%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09

Fly Intel: What to watch in Eli Lilly earnings report

Eli Lilly (LLY) is scheduled to report the results of its third fiscal quarter before the market open on Wednesday, October 23, with a conference call scheduled for 9:00 am EDT. What to watch for: 1. GUIDANCE: Along with its second quarter report in late July, the drug giant raised its fiscal year 2019 earnings per share guidance to $5.67-$5.77 from $5.60-$5.70, while reaffirming its FY19 revenue view of $22B-$22.5B. Current consensus estimates for Q3 EPS and revenue are $1.40 and $5.5B, respectively. For Q2, Lilly's revenue in the U.S. increased 1% driven by 6% volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality, and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43% of total revenue, the company noted. 2. KEY APPROVALS AND TRIALS: The U.S. Food and Drug Administration approved Cyramza as a single agent for the treatment of patients with hepatocellular carcinoma who have an alpha-fetoprotein of 400 ng/mL and have been treated with sorafenib. The FDA approved Emgality for the treatment of episodic cluster headache in adults and approved Baqsimi hypoglycemia in people with diabetes ages four years and above. The FDA granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure. 3. REVENUE DRIVERS FOR 2019: The company anticipates revenue growth to be driven by volume from key growth products including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, and Olumiant. Revenue growth is also expected to benefit from the recent launch of Emgality and could benefit from the potential approval and launch of other medicines in 2019. Revenue growth is expected to be partially offset by lower revenue for Cialis and other products that have lost patent exclusivity.

  • 23

    Oct

  • 28

    Oct

LLY Eli Lilly
$109.84

1.9 (1.76%)

09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
10/16/19
BOFA
10/16/19
INITIATION
Target $133
BOFA
Buy
Eli Lilly reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Eli Lilly with a Buy rating and $133 price target. The analyst sees the company's "high quality, differentiated growth and modest expectations for added pipeline value" as compelling.

TODAY'S FREE FLY STORIES

ESYJY

easyJet

$0.00

(0.00%)

20:35
11/19/19
11/19
20:35
11/19/19
20:35
Initiation
easyJet initiated at Goldman Sachs »

easyJet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

20:31
11/19/19
11/19
20:31
11/19/19
20:31
Syndicate
Middlesex Water 661K share Spot Secondary priced at $60.50 »

Baird is acting as lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

20:29
11/19/19
11/19
20:29
11/19/19
20:29
Initiation
Lufthansa initiated at Goldman Sachs »

Lufthansa initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

, LOW

Lowe's

$113.41

-1.62 (-1.41%)

20:25
11/19/19
11/19
20:25
11/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$110.86

0.27 (0.24%)

LOW

Lowe's

$113.41

-1.62 (-1.41%)

NTES

NetEase

$288.77

-1.33 (-0.46%)

CPRT

Copart

$86.33

0.32 (0.37%)

LB

L Brands

$17.19

-0.67 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

ICAGY

IAG

$0.00

(0.00%)

20:23
11/19/19
11/19
20:23
11/19/19
20:23
Initiation
IAG initiated at Goldman Sachs »

IAG initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$86.27

0.52 (0.61%)

20:20
11/19/19
11/19
20:20
11/19/19
20:20
Initiation
Ryanair initiated at Goldman Sachs »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFR

Luxfer

$17.57

0.16 (0.92%)

20:11
11/19/19
11/19
20:11
11/19/19
20:11
Initiation
Luxfer initiated at B. Riley FBR »

Luxfer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAL

Valaris

$3.69

-0.515 (-12.26%)

20:09
11/19/19
11/19
20:09
11/19/19
20:09
Initiation
Valaris initiated at Deutsche Bank »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$4.66

-0.16 (-3.32%)

20:03
11/19/19
11/19
20:03
11/19/19
20:03
Initiation
Transocean initiated at Deutsche Bank »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.29

-0.24 (-1.23%)

19:58
11/19/19
11/19
19:58
11/19/19
19:58
Initiation
TechnipFMC initiated at Deutsche Bank »

TechnipFMC initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$34.31

-0.36 (-1.04%)

19:53
11/19/19
11/19
19:53
11/19/19
19:53
Initiation
Schlumberger initiated at Deutsche Bank »

Schlumberger initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$8.49

-0.095 (-1.11%)

19:45
11/19/19
11/19
19:45
11/19/19
19:45
Initiation
Patterson-UTI initiated at Deutsche Bank »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safehold

$34.59

-1.33 (-3.70%)

19:38
11/19/19
11/19
19:38
11/19/19
19:38
Syndicate
Safehold 3M share Secondary priced at $34.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 20

    Nov

HP

Helmerich & Payne

$38.39

-0.45 (-1.16%)

19:36
11/19/19
11/19
19:36
11/19/19
19:36
Initiation
Helmerich & Payne initiated at Deutsche Bank »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$19.89

-0.26 (-1.29%)

19:31
11/19/19
11/19
19:31
11/19/19
19:31
Initiation
Halliburton initiated at Deutsche Bank »

Halliburton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

19:24
11/19/19
11/19
19:24
11/19/19
19:24
Initiation
Baker Hughes initiated at Deutsche Bank »

Baker Hughes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAT

Phathom Pharmaceuticals

$24.79

-0.09 (-0.36%)

19:23
11/19/19
11/19
19:23
11/19/19
19:23
Initiation
Phathom Pharmaceuticals initiated at Evercore ISI »

Phathom Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$584.48

-1.13 (-0.19%)

19:20
11/19/19
11/19
19:20
11/19/19
19:20
Downgrade
Sherwin-Williams rating change at Edward Jones »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

, SPX

S&P 500

$0.00

(0.00%)

19:17
11/19/19
11/19
19:17
11/19/19
19:17
Periodicals
Commerce Sec Ross says China trade talks still work in progress, Bloomberg says »

U.S. Commerce Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

19:10
11/19/19
11/19
19:10
11/19/19
19:10
Downgrade
Berry Petroleum rating change at KeyBanc »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

19:05
11/19/19
11/19
19:05
11/19/19
19:05
Syndicate
New York Mortgage 25M share Spot Secondary priced at $6.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LNG

Cheniere Energy

$59.77

-0.69 (-1.14%)

19:01
11/19/19
11/19
19:01
11/19/19
19:01
Hot Stocks
Cheniere Energy CEO buys 8.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

SQ

Square

$66.43

0.68 (1.03%)

18:57
11/19/19
11/19
18:57
11/19/19
18:57
Hot Stocks
Square CFO: Our mission is economic empowerment »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 10

    Dec

  • 26

    Feb

AVID

Avid Technology

$7.74

0.15 (1.98%)

, DL

China Distance Education

$7.15

0.05 (0.70%)

18:56
11/19/19
11/19
18:56
11/19/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Avid…

AVID

Avid Technology

$7.74

0.15 (1.98%)

DL

China Distance Education

$7.15

0.05 (0.70%)

ESE

Esco Technologies

$86.71

1.94 (2.29%)

BCRX

BioCryst

$2.03

0.33 (19.41%)

CTMX

CytomX Therapeutics

$5.15

-0.03 (-0.58%)

ENDP

Endo

$4.44

-0.02 (-0.45%)

AVYA

Avaya

$12.11

-0.22 (-1.78%)

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

ALC

Alcon

$59.00

0.105 (0.18%)

ORGO

Organogenesis

$8.01

0.02 (0.25%)

AMRN

Amarin

$22.74

0.11 (0.49%)

CRSP

Crispr Therapeutics

$68.46

9.94 (16.99%)

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

RIG

Transocean

$4.66

-0.16 (-3.32%)

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 05

    Dec

  • 07

    Dec

  • 28

    Dec

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

, MLNX

Mellanox

$114.40

0.245 (0.21%)

18:47
11/19/19
11/19
18:47
11/19/19
18:47
Hot Stocks
Nvidia CEO: We're at the beginning of the artificial intelligence revolution »

In an interview on…

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

MLNX

Mellanox

$114.40

0.245 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.